Some genetic abnormalities of multiple myeloma (MM) detected more than two decades ago
remain major prognostic factors. In recent years, the introduction of cutting-edge genomic …

Two mechanisms are involved in the immune escape of cancer cells: the immunoediting of
tumor cells and the suppression of the immune system. Both processes have been revealed …

Dear Editor, The use of novel therapies, such as immunomodulatory drugs (IMiDs),
proteasome inhibitors (PIs), and monoclonal antibodies (mAbs; ie, isatuximab …

This phase 2 study evaluated isatuximab as monotherapy or combined with dexamethasone
in relapsed/refractory multiple myeloma (RRMM). Patients had RRMM refractory to an …

Multiple myeloma (MM) is the second most common hematological malignancy of plasma
cells, characterized by osteolytic bone lesions, anemia, hypercalcemia, renal failure, and the …

Simple Summary CD38 remains an interesting target for anticancer therapy. Its relatively
high abundance in neoplasms and crucial impact on NAD+/cADPR metabolism and the …

Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of
clonal plasma cells. Although advances in treatment have markedly improved survival …

Purpose: To investigate the different roles of heterogeneous natural killer (NK)-cell
subpopulations in multiple myeloma and to identify NK-cell subsets that support the robust …

ABSTRACT BCMA-targeting chimeric antigen receptor (CAR)-T cell therapy has shown
remarkable clinical efficacy against multiple myeloma, yet antigen escape and tumor relapse …

Simple Summary Despite the variety of drugs used to treat multiple myeloma and the ever-
lengthening survival times, a recurring problem is that many current drugs affect healthy …